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1. SUPPLEMENTARY METHODS 
Mice and cells 
Bcl11b conditional knockout samples were obtained from two different sources: from 
Bcl11bL2/L2 homozygously floxed stock repeatedly crossed to a C57BL6/J (B6) 
background, obtained originally from Mark Leid (1, 2), and from PLBD homozygously 
floxed Bcl11bfl/fl mice with a Cre-ERT2 transgene ubiquitously expressed from the 
ROSA26 locus, as previously described (3).The Bcl11b-conditional knockout mice, 
originally (129xB6)F1 and then crossed to B6, were mostly but not completely B6 
congenic at the time of use.  Some of the animals were also crossed with (B6,129)-
ROSA26R-YFP mice, to introduce a positive fluorescent marker for successful activation 
of Cre, as already reported elsewhere (2).  Animals were bred and maintained under 
specific pathogen-free conditions in our colony at the California Institute of Technology 
under protocols approved by the Institutional Animal Care and Use Committee, with 
regular monitoring for mouse pathogens.  
 
Cell culture conditions 
To generate protocol I samples, timed pregnancies were set up and cells were harvested 
and processed essentially as previously described (1). Typically, E13.5 fetal liver (FL) 
cell samples from Bcl11bfl/fl-ROSA26R-YFP and control C57BL/6-ROSA26R-YFP mouse 
embryos were first depleted of Ter119+, CD19+ and Gr1+ cells using streptavidin-coated 
magnetic beads (Miltenyi Biotec), then sorted to purify Kit+CD27+ multi-lineage 
precursors by fluorescence-activated cell sorting (FACS; using FACSAria IIu). The 
sorted cells were then retrovirally transduced with a Cre retrovirus and incubated in 
culture with OP9-DL1 stromal cells in the presence of 5 ng/mL each of Flt3L, IL-7 and 
SCF for 24 hours. Successfully transduced cells were re-sorted for YFP expression (or for 
a fluorescent protein in the retroviral vector if ROSA26R-YFP was not present in the 
background genotype) as well as progenitor-enriched phenotype (Kit+CD27+), and 
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returned to the OP9-DL1 or OP9-DL4 stromal co-culture. After  8.5-14 days of culture as 
indicated, the cells were harvested and sorted for YFP+ DN2a phenotype (YFP+ 
Kit++CD45+CD25+Lin-) from ROSA26-YFP; Bcl11bfl/fl samples, and YFP+ DN2b 
phenotype (YFP+c-Kitint CD45+CD25+Lin-) from C57BL/6. ROSA26-YFP or other 
Bcl11b-intact controls. Here, “Lin” was detected by Lin cocktail = biotinylated 
antibodies to Ter-119, CD19, F4/80, Gr-1, NK1.1, CD122, CD11c, TCRγδ, TCRβ, CD3ε, 
CD8α and by PerCP-Cy5.5-coupled streptavidin (4). Typical profiles of the YFP+ cells 
generated from Bcl11b-floxed and control cultures are shown in Fig. S1A.   
 
Some variants of these conditions were used.  We noted that in some batches of 
medium, the controls took longer than normal to progress beyond early DN2b. The cells 
moved more rapidly to DN3 if the IL-7 level were reduced on re-feeding the cultures. 
Therefore in some of the earlier experiments we shifted down the IL-7 concentration by 
omitting it from the medium at the first cell feeding, after about 4 days. However, the 
quality of the RNA obtained in these conditions was more variable and the survival of 
control cells was lower than in higher IL-7, so later samples all used 5 ng/ml IL-7 
throughout the culture period and compensated by using longer culture times (10-12 
days rather than 8-9 days).   
 
In another variation, to test the possibility that Bcl11b deletion mimicked Notch 
inhibition, we incubated normal B6 fetal liver derived precursors to generate DN2a or 
DN2b cells as previously described (4), but with addition of 1 µM γ-secretase inhibitor 
[GSI, InSolution™ γ-Secretase Inhibitor X (EMD Millipore)] for the last 12 hr before harvest. 
This timepoint was chosen in order to allow inhibition to have an effect but not yet to 
downregulate cell-surface CD25 expression enough to interfere with subset purification 
[see (5)]. Two samples each were collected of DN2a cells with and without GSI 
treatment, and of DN2b cells with and without GSI treatment. However, at this 
timepoint gene expression changes were minimal (see heat map of effects on SOM 
metaclusters in Fig. S12, GSI column). 
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Bcl11b deletion after commitment 
For protocol II comparisons between Bcl11b knockout and wildtype samples, we 
obtained cells that had lost Bcl11b after commitment either in vivo or in vitro.  For in 
vivo deletion, fresh thymocytes were obtained from Lck-Cre;ROSA26R-eYFP; Bcl11bfl/fl 
mice and Lck-Cre;ROSA26R-eYFP controls. YFP+ thymocytes were primarily DN3 and 
later in the Lck-Cre+ Bcl11b+ controls, but the Lck-Cre+ Bcl11bfl/fl animals accumulated a 
substantial population with an altered phenotype, DN2-like with respect to Kit and 
CD25 (Kit++ CD44low CD25+), that represent arrested cells with Bcl11b deleted. This 
aberrant YFP+ population in the mutant and the DN3 YFP+ population from the controls 
were sorted for RNA analysis as described below. For in vitro deletion, we used cells 
from PLBD mice in which Cre-ERT2 ubiquitously expressed from the ROSA26 locus 
could be activated experimentally by treatment with 4-OH Tamoxifen (4-OHT). 
Normal, unperturbed DN3 thymocytes (KitlowCD44low CD25+) were sorted from PLBD 
mice and from control mice in which the ROSA26-Cre-ERT2 gene had been crossed out 
repeatedly onto a B6 background (“ERT2Cre” mice). The cells were then treated with 
100 nM 4-OHT for four days in co-culture with OP9-DL4 stromal cells. As shown in Fig. 
S1B, the controls progressed from DN3 to DN4 while the mutant cells underwent 
retrograde-appearing differentiation to a DN2-like phenotype  (repeated in 4 
independent experiments). These cells were purified from the stroma by sorting as 
before and used to generate RNA samples for RNA-seq as previously described (4). 
 
RNA-seq data analysis to define “gold standard” differentially expressed genes 
RNA-seq data were initially aligned by Bowtie and eXpress using Gencode M1 
transcriptome models. Bigwig tracks were generated for individual inspection of RNA-
seq sample quality based on relatively consistent representation of reads across 5’ and 3’ 
exons from genes across the genome. To generate a high-confidence set of differentially 
expressed genes, higher quality pairs of Bcl11b knockout and control samples were 
selected and the reads were pooled into three control and matched knockout sample 
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groups for analysis of differentially expressed genes, using EdgeR.  Data from samples 
shown in Table S5 were combined as follows.  Groups A and B consisted of Cre+ 
samples generated through a “protocol I” strategy, starting with Cre-transduced fetal 
liver hematopoietic precursors and harvesting at 8.5-12 days of culture.  Group A 
contained Bcl11b KO samples 11970, 12497 and 12501 and the respective, paired Cre-
treated controls 11969, 12499, and 12502.  Group B contained Bcl11b KO samples 11785, 
13102, and 13149 and their paired Cre-treated controls 11787, 13100, and 13148.  Group 
C contained representative samples from two “protocol II” comparisons using postnatal 
thymocytes acutely exposed to Cre to delete Bcl11b after commitment. One in vivo 
comparison pair used Lck-Cre to delete in vivo and consisted of Bcl11b KO sample 
12217 and Lck-Cre control 12886. The other close sample pair in group C consisted of 
PLBD (Bcl11bfl/fl; ROSA26-CreERT2) DN3 cells freshly sorted as controls (13218) and 
after 4 days of tamoxifen treatment to delete Bcl11b and OP9-DL4 coculture (13219). Not 
included in the gold standard sets but also analyzed to validate the wildtype initial 
phenotype of the PLBD cells were supporting controls from ROSA26-CreERT2 controls 
(ERT2Cre) both freshly sorted as DN3 and after parallel tamoxifen treatment and 
culture (13220 and 13221, respectively).  EdgeR analysis was used to identify genes 
differentially expressed between knockouts and controls with FDR <0.05 in each group.  
As reported in Table S1, the numbers of differentially expressed genes identified were 
different in the three groups and likely underestimated the number of truly regulated 
genes. Venn diagrams were used to identify transcripts that scored as significant (FDR 
<0.05) in at least two of the three groups as shown in Table S1. 
 
Multiple additional samples made by similar or matched protocols were also used for 
RNA-seq analysis but either lacked a sufficient quality control sample or had somewhat 
lower quality read distributions or lower deletion efficiency for Bcl11b in the mutants. 
These samples were not used to define the gold standard differentially expressed genes 
but were included in the larger gene list to construct the SOM. 
 
 6 
RNA-seq data alignment and gene expression quantitation for SOM 
RNA-seq read alignment and gene expression quantification were done using Rsem 
(v1.2.12) (6).  The Rsem transcriptome reference file was generated with the mm9 
reference genome and mouse GENCODE M1 gene annotation file.  For those samples 
expressing obligate repressor PU.1-Engrailed (PU.1-ENG), the PU.1-ENG sequence and 
gene annotation information were included in the reference file to accurately quantify 
native endogenous PU.1 levels(Spi1) (7).  Following gene expression quantification, 
PU.1-ENG levels were ignored.  Gene level FPKM values were merged into data matrix 
for further processing.  Small RNAs such as rRNA, tRNA, snRNA, snoRNA as well as 
miRNA were removed from the matrix and genes with < 1 FPKM in all the samples 
were also filtered out.  The data matrix was further batch corrected with ComBat (8).   
 
Self-organizing map (SOM) 
A pseudocount of 1.0 was added to the input data matrix after ComBat adjustment to 
enable logarithmic transformation. The log2-transformed matrix used as input to build a 
SOM with a toroid topology with size 40x60 with 12 million time steps using the 
SOMatic package (v.1.0) (this package can be downloaded from 
<https://github.com/csjansen/SOMatic>); the best of three tries based on fitting error 
was selected.  The SOMatic website for this mapping can be viewed at 
<http://crick.bio.uci.edu/Bcl11b_SOM/>. 
SOMs of this size can be further clustered into supersets of similar units called 
metaclusters (9) by first performing a k-means clustering on the vector values of the 
units to determine centroids. Metaclusters were built around these centroids so that 
each cluster is contiguous on the SOM topology.  After trying a range of different K 
values, a metaclustering with K=300 was chosen.  R scripts for generating metacluster 
reports are provided in the SOMatic package. 
 
Metacluster/Trait correlation and hypothesis testing analysis 
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To determine which metaclusters captured changes in gene expression due to 
experiments with similar conditions, we assigned each dataset used to train the SOM 
with a number of traits related to different developmental stages or perturbation 
conditions.  A correlation matrix is then built using the Pearson correlation between the 
columns of this trait matrix and the columns of a matrix containing the average signal in 
each metacluster in each experiment map.  A p-value can then be calculated for each of 
these correlation coefficients.  These p-values are then corrected for Type 1 error using 
the Bonferroni method and reported in a trait heatmap.   
 
To build the hypothesis maps, we used a similar process where we did a Wilcoxon test 
to see if the difference between two sets of samples is significant compared to the 
differences within each set.  Those metaclusters that show a significant increase 
between the two sets of samples are displayed in red, and those that are significantly 
depleted are shown in blue. 
R scripts for these processes are provided in the SOMatic package. 
 
Additional datasets used for comparison 
We obtained RNA-seq data for wildtype cells developing in vivo or in vitro in 
essentially the same OP9-Delta culture conditions as our experimental samples, taken 
from ref. (4).  RNA-seq data from DN2a-like cells developing in vitro after less than 24 
hr of transduction with empty vector or PU.1-engrailed obligate repressor were 
obtained from ref. (7)(Table S3). Microarray data were previously reported for Bcl11b 
knockout and wildtype DP cells various lengths of time after Bcl11b deletion in vitro or 
in vivo, from ref. (3) and ref. (10), and we extracted lists containing the genes showing 
at least twofold increases or decreases in expression from the supplementary tables in 
these papers (see Table S1E,F). Microarray data from ref. (11) were a source of lists of 
genes with fold increase or decrease ≥1.5 between E2A knockout and wildtype DN2 
cells, for the analyses described for Fig. 3 and Table S4.  Lists of transcription factors, 
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transcriptional cofactors, and chromatin modifying factors were obtained from 
AnimalTFDB (12).   
 
Chromatin Immunoprecipitation (ChIP) 
Ten million BM-derived DN3 cells, generated by culture on OP9-DL1, were fixed with 1 
mg/ml DSG (Thermo Scientific) in PBS for 30 min at RT followed by additional 10 min 
with addition of formaldehyde up to 1%. The reaction was quenched by addition of 
1/10 volume of 0.125M glycine and the cells were washed with HBSS (Gibco). Pelleted 
nuclei were dissolved in lysis buffer (0.5% SDS, 10 mM EDTA, 0.5 mM EGTA, 50 mM 
Tris-HCl (pH 8) and PIC) and sonicated on a Bioruptor (Diagenode) for 18 cycles of 
30sec sonication followed by 30sec rest, with max power. Six μg per 107 cells of anti-
Bcl11b Abs [a mixture of A300-383A (Bethyl), A300-385A (Bethyl), ab18465 (Abcam) and 
12120 (Cell Signaling Technologies)] were adsorbed to Dynabeads Protein A/G 
(Invitrogen) and added to the diluted chromatin complex. They were incubated over 
night at 4°C, then washed and eluted for 6hr at 65°C in ChIP elution buffer (20 mM Tris-
HCl, pH 7.5, 5 mM EDTA 50 mM NaCl, 1% SDS, and 50 μg proteinase K). Precipitated 
chromatin fragments were cleaned up using Zymo ChIP DNA Clean & Concentrator 
and subjected to quantitative PCR on a 7900HT Fast Real-Time PCR System (Applied 
Biosystems) with SYBR GreenER qPCR SuperMix (Invitrogen).  
Primers used for ChIP-PCR: 
Zbtb16 intron 2  
FW; 5’-ggtgctgcaggagtaagca-3’ 
RV; 5’-ttgacaggagcaaaccagatt-3’ 
Tnni1 intron 6 
FW; 5’-aaaatgggggtcccagtatg-3’ 
RV; 5’-ccacaatgaagggctgagtc-3’ 
Dntt intron 3  
FW; 5’-cttttcagttcagtgacagagtcc-3’ 
RV; 5’-gcctttggagtcaggatcaa-3’ 
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Cd3d exon5 
FW; 5’-ttgtcttagcttggctgagttct-3’ 
RV; 5’-gaagctgtccctcgtactgc-3’ 
Igκ 3’UTR 
FW; 5’-ggcacatctgttgctttcgc-3’ 
RV; 5’-ggggtagggagcaggtgtat-3’ 
Gapdh promoter 
FW; 5’-gcagcaagggttgcattt-3’ 
RV; 5’-ttgtctgtactgggctgtttacat-3’ 
Il4 promoter 
FW; 5’-tgactctggggtcttacctcat-3’ 
RV; 5’-tctccaaagaccacaaacttgtaa-3’ 
 
Chromatin Immunoprecipitation (ChIP) and ChIP-sequencing 
ChIP-seq libraries were constructed using NEBNext ChIP-Seq Library Preparation Kits 
(NEB #E6240) following the manufacturer’s instructions. Libraries were sequenced on 
an Illumina HiSeq2500 in single read mode with the read length of 50 nt following 
manufacturer's instructions. Base calls were performed with RTA 1.13.48.0 followed by 
conversion to FASTQ with bcl2fastq 1.8.4, and produced approximately 30 million reads 
per sample. ChIP-seq data were mapped to the mouse genome build NCBI37/mm9 
using Bowtie (v1.1.1; http://bowtie-bio.sourceforge.net/index.shtml) with “-v 3 -k 11 -
m 10 -t --best –strata” settings, and HOMER tagdirectories were created with 
makeTagDirectory. Bcl11b peaks were identified with findPeaks.pl against a matched 
control sample using the settings “-P .1 -LP .1 -poisson .1 -style factor”. Bcl11b peak 
reproducibility was determined by a HOMER adaptation of the IDR (Irreproducibility 
Discovery Rate) package according to ENCODE guidelines 
(https://sites.google.com/site/anshulkundaje/projects/idr). Only reproducible high 
quality peaks, with a normalized peak score ≥ 15, were considered for further analysis. 
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Motif enrichment analysis was performed with the findMotifsGenome.pl command in the 
HOMER package using a 200bp window. Consistent with the varied roles of Bcl11b 
both in direct DNA binding and in binding via other transcription factors (13), Bcl11b 
ChIP-seq peaks were not dominated by a single specific motif. However, ETS-family 
and Runx-family motifs were by far the most highly enriched at the ~20,000 high-
quality Bcl11b occupancy sites (>40% of sites, and >25% of sites, respectively; both P 
values <1E-1500; see Fig. S8H). 
 
 
Quantitative real-time RT-PCR (qPCR) 
Two to three PLBD, ERT2Cre, or C57BL/6J 6-12 wk old age-matched mice were pooled 
for each replicate as indicated. To isolate DN populations, mice were sacrificed, their 
thymuses were removed, and single-cell suspensions were made. Mature cells were 
depleted by staining with biotinylated Abs to CD8a (53-6.7), TCRγδ (GL3), TCRβ 
(Η57597), Ter119 (Ter119), NK1.1 (PK136), CD11c (N418), and CD11b (M1/70), after 
which the cells were incubated with streptavidin-coated magnetic beads and then 
passed through a magnetic column (Miltenyi Biotec, Auburn, CA). Eluted DN cells 
were stained with CD117 (cKit)-PE (2B8) CD25-APCe780 (PC61.5). Kit-low, CD25+ DN3 
cells were purified by FACS and cultured on OP9 DL1 monolayers for 4 days. 1.0x105 
PLBD DN3 cells were frozen as a pellet in the -80 as a pre-treatment, “day 0” control. 
After sorting, cells were treated with 100nM 4-OHT for 44-48 h (as in “Bcl11b deletion 
after commitment”, above). Sigma 4-OHT (H7904) was reconstituted in EtOH to 1mM 
and further diluted in OP9 media for treating cells.  On day 4 post-4-OHT-treatment, 
CD25+ cells from PLBD and controls were purified by FACS, noting that while the 
controls further downregulated Kit and most controls also downregulated CD25 
expression (transitioning through β-selection), the induced Bcl11b-knockout cells 
generally increased or at least maintained cell-surface Kit expression. cDNA was 
prepared from total RNA using RNeasy extraction kits (Qiagen) and reverse transcribed 
using random hexamers and SuperscriptIII (Invitrogen). Specific gene expression in 
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cDNA samples was measured by qPCR (ABI Prism 7900HT) using SyberGreenER mix 
(Invitrogen). Results were calculated (∆ Ct method) and normalized to Actinb levels. 
Primers used for qPCR were described previously [Actb exons 1-2; Kit (5)], or are as 
follows:  
Zbtb16 FW 5’- GTG CCC AGT TCT CAA AGG AG -3’ 
Zbtb16 RV 5’- GAA AGC GTT TCC CAC ACA G -3’ 
Tnni1 FW 5’- GAA TGT GGA GGC TAT GTC TGG -3’ 
Tnni1 RV 5’- TGT CAT ACA GCA AGC CAA CC -3’ 
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2. SUPPLEMENTARY TEXT:  
DETAILED REVIEW OF T-CELL GENE REGULATORY NETWORK MODEL 
Situating Bcl11b in the larger gene network framework 
 
The new results defining Bcl11b targets enable us to add new linkages to the T-cell 
specification gene regulatory network (14) relating the T-cell fate to other pathways. 
This update also includes recent data for gene expression changes caused by E2A 
deletion (11), or acute PU.1-antagonism (7) in DN2 cells developing from fetal 
precursors, and for the interaction of Notch signaling with PU.1 gain of function effects 
in DN2 cells and a DN3-like cell line (15), as well as recent dissection of the “and” logic 
regulators driving the activation of the Bcl11b gene itself in the DN2a stage(16). The new 
comprehensive model is shown in Fig. 1 and elements of the circuits controlled by 
Bcl11b in Fig. 4. The major transitions in T-cell developmental gene regulation (4) occur 
between DN2a and DN2b, and then again between DN3a and post-β-selection stages 
(DP), which we have termed the boundaries between “phase 1” and “phase 2”, and 
between “phase 2” and “phase 3”, respectively (17).  In the following, “phase 1” refers 
to genes that are expressed in the ETP (DN1) and/or DN2a stages, whereas “phase 2” 
refers to genes that are expressed in stages from DN2b through DN3a. The phase 1-
phase 2 boundary also coincides with lineage commitment, distinguishing the states 
shown in Fig. 1A and Fig. 1B, respectively.   
 
Commitment tightly coincides with the activation of Bcl11b expression (16). With its 
relatively late onset, this is not simply a direct response to Notch signaling. To explain 
the timing of commitment, at least five other transcription factors have to be included 
(2, 16, 18-21): Runx1, E2A, Hes1, GATA-3, and TCF-1 (see Fig. 2C). Runx1 (and other 
Runx family members) and E2A (encoded by Tcf3) are already expressed at high levels 
by the precursors when they enter the thymus, and both play continuing roles 
throughout the process. E2A levels are quite constant, but its T-cell heterodimerization 
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partner HEB (Tcf12) is upregulated during the DN2a-DN3a progression, while its 
stem/progenitor heterodimer partner Lyl1 is downregulated (4, 5)(Fig. 2B), and this 
could affect some aspects of its role. Hes1 is a repressive bHLH factor that is directly 
activated by Notch signaling in ETPs and expressed through all the DN stages, but is 
expressed in early B cells as well. GATA-3 and TCF-1 (encoded by Tcf7) are 
substantially T-lineage specific. Both are upregulated in a Notch dependent way at ETP 
stage, and Tcf7 at least is a direct Notch target (22, 23). Bcl11b is turned on and its role 
begins while PU.1 is still present, and under the aegis of all these factors’ activities (16). 
 
Also expressed through these stages and globally important for T cell development are 
Gfi1 and Ikzf1 (Ikaros), encoding two zinc finger transcription factors (24-26), and Myb, 
which is significant even into the DP stage (27, 28) and may provide some positive 
input to Gata3 (15, 29). Gfi1 is thought to be activated in an E protein-dependent way 
(11, 30), and may, like Bcl11b, repress Id protein expression (31, 32)(not shown in Fig. 1). 
Ikzf1 is expressed in many non-T hematopoietic cells, but detailed analysis of Ikzf1 
regulatory elements suggests that Runx and TCF-1 sustain its T-cell specific expression 
(33), whereas the binding of E proteins also observed at this locus (33) may actually 
have a damping negative effect on Ikzf1 in pro-T cells (11, 15)(Fig. 1). Ikaros has recently 
been shown to be needed to enforce sharp transitions in global developmental gene 
regulation during T-cell specification, though the mechanism is not clear (26). It has also 
been implicated in damping expression of some Notch response genes in later T-cell 
developmental stages (34, 35), but the relevance of this mechanism to the stages around 
commitment is not known.  
 
Phase 1 Network: PU.1 and Notch to PU.1 shutoff 
Notch1 regulation: a key role for E proteins.  Notch signaling in early T cells depends 
strongly on bHLH E protein activity, mostly E2A, which directly regulates Notch1 
expression and signaling from prethymic stages through DN3 stage (15, 36-38). Target 
genes of E proteins have been inferred from E2A knockout and inducible E2A addback 
 14 
experiments (30, 37, 39), from E2A binding in DN3 cells in vivo (40), and from the acute 
effects of forced expression of the antagonist Id2 (15). As both Id2 and Id3 are normally 
low in phase 1 pro-T cells (Fig. 2B)(41), the only endogenous modulators of this critical 
input to Notch1 during phase 1 to early phase 2 appear to be heterodimer partners of 
E2A, namely Lyl1 which predominates during phase 1 (42), and HEB (Tcf12 gene 
product) which predominates during Phase 2 (43). Both support high Notch1 expression 
even from prethymic stages, well before Bcl11b is activated. 
 
Phase 1 regulatory gene set. The precommitment “phase 1” period is defined by strong 
expression of the B-cell, dendritic-cell, and myeloid-cell associated transcription factor 
PU.1 (encoded by Spi1, alias Sfpi1), and a set of stem-cell associated growth factor 
receptor and regulatory genes including Erg, Mycn, Hhex, Bcl11a, Gfi1b, Kit, and Lyl1 
[reviewed by (17)]. Cells within the ETP population, presumably very early phase 1 
cells, also express Flt3, Mef2c, and Lmo2. This regulatory gene combination overlaps the 
10-gene stem/progenitor-cell signature (44) and includes multiple T-lineage proto-
oncogenes (17). Interestingly, another one of the phase 1 genes is a highly Notch-
dependent gene, Nrarp, which acts as a negative feedback regulator of Notch signaling 
itself (45, 46).  Silencing of all these phase 1 regulatory genes is a major landmark of 
commitment.  
 
Different alternative fates are initially restricted using different parts of the T-cell 
network, not a single “master” switch. Hes1 antagonizes the myeloid fates via 
repression of Cebpa (21). TCF-1 and GATA-3 are antagonistic with the B cell fate (2, 47-
49), but are embedded within the ILC as well as the T-cell programs [reviewed by (50, 
51)]. Whereas PU.1 is an obvious bridge to the myeloid fates (15, 52-54), and its 
silencing may break that bridge, the fates that Bcl11b is mainly suppressing depend on 
factors that are initially silent in phase 1 before Bcl11b is turned on. In this light, the 
phenotype of Bcl11b knockouts reveals that Bcl11b repression targets gain potential 
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activity during commitment, not lose it, and then remain conditionally activatable, long 
into T cell development.  
 
PU.1—Notch mutual antagonism. Myeloid and dendritic potential of T-cell precursors 
probably depends on PU.1, but loss of function experiments show that PU.1 at normal 
levels is needed for optimal proliferative expansion of ETP and DN2a/2b cells alike (7, 
55). Although it appears to limit the pace of T-cell differentiation, PU.1 in normal 
thymocytes does not promote transdifferentiation to myeloid or dendritic cell fates in 
vivo. This is at least partly because strong Notch signals like those in the thymus keep 
PU.1 action compatible with the T cell program (15, 52, 54). There is a specific mutual 
antagonism between Notch signaling and PU.1, although PU.1 and Notch1 do not 
repress each other’s expression transcriptionally. Instead, Notch signaling selectively 
prevents activation of the myeloid programs by PU.1. This may be because PU.1’s 
myeloid partner Cebpa is kept repressed by Notch-induced Hes1 (21). However, strong 
Notch signaling still allows PU.1 to activate progenitor-cell associated regulatory genes 
including Bcl11a, and in some contexts Lmo2 (7, 15). In turn, if Notch signaling is low, 
PU.1 can repress key T-cell regulatory genes including Tcf7, Gata3, Zfpm1 (GATA-3 
cofactor FOG1), Hes1, Ets1, and Myb, and at sufficiently high levels, PU.1 can inhibit 
Notch signaling itself (15)(Fig. 1A). Thus PU.1 establishes a threshold for effective 
Notch signaling and Notch signaling filters PU.1 impacts. 
 
PU.1 targets: complex modes of developmental regulation. PU.1 binds many more 
genomic sites than genes that it regulates (4), so perturbation is essential to define its 
targets. Because PU.1 protein has a very long half-life (56), and because its deletion 
reduces cell yield, we have used an obligate repressor form of PU.1 to perturb its 
activity acutely and competitively, to probe PU.1-dependent transcriptional circuitry 
and to generate samples for global RNA-seq analysis (7). The results have yielded four 
take-home lessons (7). First, endogenous PU.1 not only delays expression of T-cell genes 
but also negatively regulates another set of alternative-lineage genes. Notably, these 
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turn out to be key NK and ILC genes including Il2rb and Zbtb16, which are also 
repressed by Bcl11b in phase 2 cells. Second, many of PU.1’s repressive effects appear to 
be indirect. This is implied since the obligate repressor form of PU.1 does not mimic the 
repressive effects of wildtype PU.1, but rather enables cells to express even higher levels 
of its NK-lineage and T-cell associated repression targets (7). However, the mechanism 
of this repressive effect is still under investigation. Third, PU.1 effects on other members 
of its own cohort of phase 1 regulatory genes are gene-specific. While wildtype PU.1 
positively regulates some phase 1 genes, like Bcl11a, Lmo2, and Mef2c, it appears to exert 
moderate damping repression on others like Gfi1b, Kit, Mycn and Erg despite their 
normal expression pattern strongly overlapping with PU.1 (Fig. 1A). Through its Notch-
signal inhibitory effect and/or directly, elevated levels of PU.1 can also repress the 
Notch-dependent phase 1 gene Nrarp, even though it is also normally coexpressed with 
PU.1 in early pro-T cells. Finally, the genes most vulnerable to the PU.1 obligate 
repressor are enriched for cell biology and signaling genes, encoding growth factor 
receptors, cytoskeletal and adhesion regulators, kinases, and heterotrimeric G-protein 
coupled receptor signaling components, implying that these are many of the genes that 
endogenous PU.1 activates in unperturbed phase 1 cells (Table S3)(7).  
 
How PU.1 limits Notch responses is not known. One known negative regulator of 
Notch signaling, the feedback inhibitor Nrarp, is actually vulnerable to negative 
regulation by PU.1 as noted above, the opposite response from what would explain 
PU.1’s effect on Notch. Other conventional Notch inhibitors (e.g. Numb, Spen) are not 
found among the PU.1-dependent targets. Conceivably some PU.1 effects, such as 
blunting Notch signaling in early T cells, may be established by activating cross-acting 
signal pathway mediators or affecting cell surface dynamics so as to interfere with 
Notch activation biochemistry. 
 
Transition from phase 1 to phase 2 
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GATA-3, dose dependence, and incoherent circuits. The early action of Notch signaling 
turns on both Gata3 and Tcf7 (encoding TCF-1) in ETP/DN1 stage, while the phase 1 
regulatory factors are still prominent. As the cells begin to turn on a DN2 surface 
phenotype, they also strongly upregulate Il7r, which, at first in combination with Kit, 
exerts an increasingly potent stimulus to cell proliferation and survival. GATA-3 and 
TCF-1 then collaborate with Notch and Runx1 to bring about the transition to phase 2. 
GATA-3 rapidly becomes important for survival of the ETP/DN1 cells. At physiological 
levels, GATA-3 helps to establish TCR expression and promotes expression of Kit, Ets1, 
the gene encoding its own cofactor Zfpm1, and later Bcl11b, while restraining PU.1 and 
several PU.1 target genes (2, 15, 47, 57)(Fig. 1). However, GATA-3 is highly dose-
dependent in its actions and must have its expression tuned by “soft” damping-type 
repression. GATA-3 genomic site occupancy is acutely stage-dependent even when its 
levels are nearly constant (4), implying that it is titrated to occupy regulatory sites 
effectively where, and only where, other factors or chromatin conditions assist. Even a 
fewfold downregulation of GATA-3 protein causes cell death (2), but overexpression in 
the same stages can also abort T cell development and/or promote redirection to a 
mast-cell fate (11, 58).  The Gata3 enhancer has sites for inputs from TCF-1, E proteins, 
and the Notch-interacting transcription factor RBP-J (59), but it has a variety of 
restraints on it. As noted above, in low Notch signaling PU.1 can reduce GATA-3 
protein levels (15). Under strong Notch signaling, once Gata3 is induced, E2A must limit 
Gata3 expression to sustain T-cell development (11, 15). Furthermore, Gata3 expression 
rises slightly in many Bcl11b knockout samples in this study, suggesting that Bcl11b 
again parallels E2A to provide restraint. 
 
Phase 1 to Bcl11b. The onset of expression of Bcl11b marks the transition to phase 2 (Fig. 
1B), followed by upregulation of multiple factors that reinforce the initial specification 
factors (see below)(5). Using a nondisruptive fluorescent reporter allele of Bcl11b to 
dissect inputs to Bcl11b activation at the single cell level (16), we have shown that Bcl11b 
activation depends on Notch signaling, GATA-3, TCF-1, and Runx1. This appears like 
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classic “AND” logic, useful for stringent cell type specificity. However, shRNA 
knockdown of candidate transcription factors at different stages before commitment, or 
removal of the cells from Notch signals, reveal that the critical time window for action 
of at least two of these regulators is confined to ETP stage, i.e. well before actual 
expression of Bcl11b. GATA-3, TCF-1, and Notch signaling appear to act in a hit-and-
run way, controlling the probability that a given Bcl11b allele will be activated but not 
regulating expression amplitude by the time the gene is expressed. Surprisingly, of 
these factors it is only Runx1, the one input of the four that is already expressed before 
T-cell specification, that provides the immediate amplitude control for Bcl11b both in 
turning its expression on and in sustaining it, with or without Notch signaling (16)(Fig. 
1B).  The asynchronous behavior of these four combinatorial inputs strongly implies 
that discrete functions are needed to prepare the Bcl11b locus for activation, distinct 
from those needed to control transcriptional initiation once it is active. Note that in pre-
commitment cells Bcl11b is silenced by H3K27me3 polycomb repressed marks on the 
chromatin and substantial CpG methylation on the DNA (60)[and data from (61)], 
marks which need to be removed or modified. Similar repressive mark removal occurs 
on a distal enhancer for Bcl11b, 850 kb downstream (60). The asynchrony of action 
among GATA-3, TCF-1, and Runx1 could reflect a division of labor between chromatin 
opening functions and active transcriptional initiation rate control. 
 
PU.1 silencing. PU.1 silencing is important for eliminating access to dendritic-cell, 
myeloid, and possibly mast-cell fates given that all these alternative programs depend 
on it or are promoted by it (62, 63).  The termination of its expression depends on many 
of the same inputs as Bcl11b activation: Runx family factors, probably Runx1 in this 
context (19, 20); GATA-3 (2, 58); and TCF-1 (18)(Fig. 1A). Bcl11b itself does not appear to 
be directly required, especially since PU.1 is ultimately repressed in NK cells which lack 
Bcl11b as well as in T cells. Runx1 is important to activate PU.1 in early hematopoietic 
precursors (19, 64), but in early T cells it represses PU.1 through multiple contacts at its 
major enhancer and a secondary silencing element (19, 20, 65). GATA-3 dosage 
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dynamically affects PU.1 levels by the DN2-3 stages (2, 58). Knockdown of TCF-1 in 
DN2 stage cells can also greatly increase diversion to dendritic cells, a PU.1-promoted 
fate, instead of T cells (16).  
 
Other changes in the phase 1 to phase 2 transition 
Ets1 activation and Runx paralog shift.  As pro-T cells undergo commitment, there is 
upregulation of a variety of T-cell genes.  Some are late-activated Notch target genes, 
whereas others encode additional members of regulatory factor families. Early T-cell 
development includes expression of multiple Ets family transcription factors, but DN2a 
to DN2b is a stage when there is substantial upregulation of the eponymous founding 
member of the family, Ets1 (5, 41).  Ets1 is important not only for T cell development but 
also for NK cell and one subtype of innate lymphoid cell development as well (66-68).  
Ets2 also begins to be expressed at this stage. Over the next few stages, other Ets family 
factors including Elk3 and Etv6 as well as PU.1 are downregulated, with Erg turned off 
slightly later (5, 41).  The increased expression of Ets1 may depend on PU.1 
downregulation, since PU.1 negatively regulates Ets1, while GATA-3, which peaks in 
DN2a/2b stage, somewhat upregulates it (2, 15, 54)(Fig. 1B).  In parallel, expression of 
Runx family members shifts so that Runx3 and Runx2, which are both expressed in ETP 
(DN1) cells, are downregulated while Runx1 is upregulated, in part activated by E 
proteins (11, 15).  As Runx and Ets factors frequently collaborate, these coincident 
paralog swaps increase the possibility that different family members have different 
function on target genes, even if they work through the same target DNA binding sites.   
 
Lef1 activation and control by TCF-1.  TCF-1 (encoded by Tcf7) is important for T-cell 
development from an early stage and is upregulated initially in ETP (DN1) stage (22, 
69). Full-length TCF-1 can act in an autoregulatory positive feedback to promote Tcf7 
expression, as well as promoting other T-cell regulatory gene expression and blocking B 
cell development (23).  By DN2b stage, a paralog of Tcf7, Lef1, is also strongly activated, 
partly under the control of Notch signaling and partly driven by TCF-1 (Fig. 1B). 
 20 
However, the most abundant isoforms of TCF-1 expressed in the thymus are not full-
length, but truncated structural variants that are biased for repression rather than for 
activation (70).  These isoforms act to set a damper on Lef1 expression levels, a function 
important to prevent leukemia (70, 71), and possibly also to delay timing of Lef1 
activation (Fig. 1A). In addition to participation in binding ensembles at many active 
enhancers (72), roles of TCF-1 have been inferred for repression of Spi1 (Sfpi1, PU.1) as 
well as for downregulation of Lef1, but it is not clear yet which roles of TCF-1 are 
unique and which can be mediated by LEF-1 as well. 
 
Modulation of growth factor signaling by Bcl11b.  Bcl11b acts not only to repress phase 
1 genes and non-T cell genes, but also to modulate growth behavior of the cells.  When 
Bcl11b is deleted, Il2rb and Kit are consistently upregulated, but Il7r is also consistently 
well expressed, albeit not as consistently above the controls (1). The combination of 
higher Kit and strong IL-7R expression is functionally effective to sustain proliferation 
in vitro if cells have lost Bcl11b before commitment, although for unknown reasons the 
same growth factor gene upregulation is not effective after commitment.   
 
TCR gene activation.  Expression of T-cell receptor genes depends on a complex 
recombination mechanism as well as transcriptional activation, so it is mostly outside of 
the scope of this GRN model.  Rag1 and the mutagenic polymerase Dntt, which are 
important for the recombination process, are linked into the network as targets of E 
proteins (11, 30, 37, 39), with GATA-3 providing additional input to Rag1 (47) and 
Bcl11b into Dntt as shown in the present study. However, three sets of TCR-coding gene 
segments are also rendered accessible transcriptionally and thus opened for 
recombination during the stages immediately following commitment: the Tcrb locus, 
the Tcrd locus which is embedded in the center of the Tcra locus, and the complex 
cluster of recombination units making up the Tcrg loci. Several regulators in the GRN 
model directly affect activity of these loci. The Tcrb locus appears to receive positive 
inputs from Ets1, Runx1, GATA-3, and E proteins (73-76), but the most significant 
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functionally is the stringent requirement of the Tcrg locus for Stat5a/Stat5b input 
triggered by IL-7 receptor signaling (77, 78). Whereas most Tcr gene complex 
rearrangement is positively regulated by E proteins (79), the first fetal lineage of TCRγδ 
cells is also distinctive for its preference for low E protein and unusual tolerance of high 
Id2 levels (80), which are typical of the early fetal thymus (81).  Bcl11b-deficient pro-T 
cells are very severely blocked in TCRαβ T-cell development but not completely 
blocked in TCRγδ T-cell development, and this can be related to the different regulatory 
requirements of these different Tcr complexes for opening.  
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SUPPLEMENTARY TABLE LEGENDS 
 
Table S1: Identification of Gold Standard Bcl11b Knockout gene sets and comparison 
with previously published Bcl11b knockout results 
A: Lists of Gold Standard genes upregulated and downregulated in Bcl11b knockouts. 
B. and C.: Genes with actual log2 fold change levels, listed by each component 
comparison of sample tracks that was used to identify the gold standards. Positive log2 
fold change levels indicate upregulation when Bcl11b is deleted.  B: Genes in each 
component listed in order of false discovery rate (all <0.05).  C: Genes in each 
component list after removal of miR and Gm transcripts, listed in order of fold change 
between Bcl11b knockout and wildtype.  D: For reference, in addition to the intersection 
list shown in A, a union list is provided of all the genes showing up as significant in any 
of these three comparisons.  E. and F.: Venn diagram comparison of the Gold Standard 
list of Bcl11b-knockout sensitive genes with genes identified in previous studies (3, 10).  
E: comparison of genes upregulated in Bcl11b knockouts. F: comparison of genes 
downregulated in Bcl11b knockouts.   
 
 
Table S2: Metacluster identities of genes in Self Organizing Map and gene 
expression regulator representation in Bcl11b-regulated genes 
A: List of memberships of each metacluster in the SOM, with each gene in a metacluster 
annotated by the coordinates of the component cluster it falls within.  Memberships of 
all metaclusters (#0-299) are given.  Note that clusters and metaclusters are defined by 
similarity of expression patterns, and do not contain equal numbers of genes.  B: Genes 
in metaclusters associated with different responses to Bcl11b deletion, which also 
encode annotated transcription factors, chromatin regulators, or transcription cofactors.  
The metaclusters considered to fall into different classes of Bcl11b response are listed at 
the top.  Then the lists of genes encoding transcriptional regulators (12) in each class are 
presented. 
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Table S3: Overlap of Bcl11b gold standard genes with PU.1 obligate repressor-
sensitive target genes 
Lists of genes shown to be acutely down or up regulated by the PU.1-Engrailed obligate 
repressor are presented, with the gold standard lists of Bcl11b-knockout affected genes.  
Genes upregulated and genes downregulated in the Bcl11b knockout samples are each 
presented with the lists of genes that are also affected (up or down) by the PU.1 obligate 
repressor.  Note that although there are overlaps in all four combinations, there is little 
bias for a Bcl11b effect to be in the same or the opposite direction from the PU.1 
antagonist effect. 
 
 
Table S4: Overlap of Bcl11b gold standard genes with E2A- sensitive targets 
A: Bcl11b knockout gold standard gene lists. B: Lists of genes affected by ≥1.5 x in E2A 
knockout DN2 cells as compared with control DN2 cells, from ref. (11).  C: Venn 
diagram overlap of representation of Bcl11b knockout upregulated genes, among E2A 
up- or down-regulated genes. Note the highly biased pattern of overlap.  D: Venn 
diagram overlap of representation of Bcl11b knockout downregulated genes, among 
E2A up- or down-regulated genes.  Note the low but also biased pattern of overlap.  A 
χ2 calculation (2x2) yields a chi-square statistic of 18.2609, p-value 0.000019.  
 
 
Table S5: Characteristics of RNA-seq samples 
The Table presents the characteristics of the RNA-seq samples used in this study.  
Experimental conditions are included in the descriptive names, column A. Column A 
also indicates whether the cells were Bcl11b knockout (“KO”) or controls.  Columns B & 
C report the short name and sequence track number. Columns D-K present trait scoring. 
Column O describes the source of the input material: most of the samples are in vitro-
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differentiated DN cells derived from fetal liver hematopoietic precursors, but whether 
or not the precursors were frozen before use is reported in this column.  Column P 
reports the IL-7 concentrations used in the cultures, if any.  Column Q indicates the 
genetic background.  YFP= mouse strain includes ROSA26R-eYFP as a Cre 
recombination indicator gene. These samples were sorted on YFP as well as on 
Kit/CD44/CD25 phenotype. Note that both Bcl11bfl/fl transgenic lines in our study 
were repeatedly bred to B6 stock but could not be presumed to be fully congenic at the 
time these samples were harvested. They are therefore indicated as (129,B6) genetic 
background.  Color annotations indicate whether the samples were published and the 
data deposited before this study (yellow), and if the samples were part of the gold 
standard set, the group they were included in is indicated.  Green: group A, protocol I.  
Blue: group B, protocol I.  Rose-gray: group C, protocol II. 
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SUPPLEMENTARY FIGURE LEGENDS 
 
Figure S1.Phenotypes of pro-T cell developmental progression with and without the 
Bcl11b gene.  A) Characteristic differentiation profiles of control and Bcl11b-knockout 
cells developing from fetal liver precursors in a protocol I comparison.  Fetal liver 
precursor cells from the indicated genotypes with a ROSA26R-eYFP Cre recombinase 
reporter were Cre-transduced prior to initiation of T-cell differentiation culture.  Panels 
show phenotypes of the YFP+ cells after 9 or 12 days of culture. Cartoon below shows 
pro-T cell developmental stages corresponding to different phenotypes.  Note 
pronounced delay in downregulation of Kit in Bcl11b-deficient cells and persistence of 
some CD44 expression as control cells generate Kitlow CD44low true DN3 cells.   B) 
“Retrograde” differentiation in DN3 cells acutely deprived of Bcl11b after commitment.  
PLBD mice and control mice with the ROSA26-CreERT2 gene crossed out to a B6 
background were used as sources of fresh DN3 thymocytes, sorted from Lin-  DN 
thymocytes as indicated in the top row (day 0).  Sort gates to purify DN3 cells are 
shown on the figure. The cells were then incubated for 4 days in OP9-DL4 co-culture 
with 100 nM 4-OHT to activate Cre.  Lower row (day 4) shows that while the control 
cells progress rapidly through DN3 to DN4 stage, the Bcl11b-deleted PLBD cells acquire 
a DN2-like Kit-high phenotype.  (Flow cytometry plots came from FACSAria IIu sorter 
for top row and from MACSQuant analyzer in the bottom row.) 
 
 
Figure S2: RNA-seq profiles of key genes in Bcl11b KO and control cells. Figure 
shows UCSC genome browser displays of RNA transcript levels for 12 genes in controls 
at different stages and in Bcl11b knockout cells.  Within each panel, all the vertical 
scales are identical, ranging from backgrounds of 0.02 fpm (fragments per million 
reads) to maxima scaled to the peak expression of the genes shown (1 fpm to 50 fpm in 
different panels). Gene names and scale bars are shown at the top of each panel.  Panels 
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show Bcl11b itself, to document the efficiency of deletion; Bcl11b-dependent genes Gbp4 
and the Cd3g, Cd3d, Cd3g cluster; and Bcl11b-repressed genes Tnni1, Itga2b, Tyrobp, 
Fcer1g, Cxcr5, Zbtb16, Nfil3, Id2, and Il2rb. All of these targets qualified as members of 
the “gold standard” gene sets except Nfil3, which is consistently upregulated in Bcl11b 
knockout cells made by Protocol II (see Fig. S1) but more weakly, though again 
consistently, upregulated in cells made by Protocol I.  Of these genes, Itga2b, Tyrobp, and 
Fcer1g illustrate examples of genes normally expressed in a phase 1 pattern (specific for 
DN1 or ETP & DN2a) but further upregulated or delayed in downregulation when 
Bcl11b is absent.   Black traces: control cells of indicated developmental types.  Red 
traces: Bcl11b knockout DN2-like cells.  Top four lanes: two independent pairs of Bcl11b 
knockout and control samples. Bottom three lanes: normal developmental series from 
DN1 (ETP) to DN2b (newly committed). Green box in Bcl11b gene plot shows exon 4, 
the part of the gene that is deleted in the knockout.  This exon encodes 5 of the 6 zinc 
fingers of the Bcl11b protein that include the DNA binding and protein interaction 
domains (82), so loss of signal over this exon means Bcl11b is inactivated functionally.  
A hallmark of this deletion, a property of both independently derived Bcl11bfl/fl mouse 
lines used in this study, is that transcripts from the rest of the gene do not disappear but 
splice to a cryptic downstream exon before terminating. Rectangles in Cd3 cluster, 
Itga2b, Fcer1g, and Cxcr5 plots indicate region containing the relevant transcripts in 
these more crowded genomic regions.  
 
 
Figure S3. Characterization of gold standard sample panel in terms of intrinsic 
developmental state clock.  A) Heat map of differential expression of 90 pro-T cell 
regulatory genes (rows) in control and Bcl11b knockout samples of the gold standard 
panel set (columns).  These index genes are useful for defining early T-lineage 
developmental progression in principal component analyses (7).  Despite all being 
sorted in the DN2-DN3 stage interval, note that there is a range of states among the 
samples such that controls especially differ in terms of global “maturity”as defined by 
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this panel of regulatory genes.  B) The hierarchy of expression of these genes in normal 
development is shown by listing the genes in order of their weightings along Principal 
Component 1, which roughly captures advancement through development from DN1 
(ETP) all the way to DP stage. High values for weightings along Principal Component 2, 
also provided, strongly separate DN3 cells poised for β-selection from earlier and later 
T-cell precursors (7). C) Pairwise comparisons of RNA-seq read counts between ten 
pairs of Bcl11b-knockout and matched control samples (generated, Cre-treated, and 
processed in parallel in the same experiment).  Bcl11b itself and 12 target genes are 
shown with p-values for each difference calculated by paired Student’s t test.  The total 
signal for Bcl11b itself is reduced, despite a lack of Bcl11b autoregulation, because the 
deleted exon includes most of the coding sequence of the Bcl11b gene. 
 
 
Figure S4.  Examples of RNA-seq track sets across multiple Bcl11b knockout, control, 
and reference samples.  The figure shows the specific, repeatedly observed 
upregulation or deferral of downregulation of three Phase 1 genes in Bcl11b knockout 
cells: (A) Cd7, (B) Kit, and (C) Bcl11a. Samples from Bcl11b knockout cells are indicated 
as red tracks, samples from controls (Cre treated or reference control) are shown in 
black, and a set of reference samples treated with γ-secretase inhibitor to test for effects 
of Notch pathway inhibition are shown in dark blue.  Arrows at the top of each panel 
show the direction of transcription of the gene indicated, and brackets connect the pairs 
of samples that were generated as knockout & matched control within the same 
experiment. The five samples at the bottom of each panel are unperturbed reference 
samples from (4)(FLDN = in vitro differentiated DN cells from fetal liver precursors; 
Thy = purified from adult thymus), included to relate the knockout phenotype to 
normal developmental changes of expression.  The group of six samples at the top 
represent adult thymus-derived cells in which Bcl11b was deleted after commitment 
(Protocol II); with the exception of one other adult thymic DN3 control sample 
(ThyDN3ctrl+Cre); all the remaining samples were generated under Protocol I 
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conditions.  All the vertical scales for all samples are the same in a given panel, from 
backgrounds of 0.02 fpm to maximum values of 5 fpm (Cd7, Kit) or 1 fpm (Bcl11a). As 
all these genes are Phase 1 genes, the normal patterns of expression decrease markedly 
from DN2a (FLDN2a) to post-commitment stages, ThyDN3 or ThyDP. The figure shows 
that despite quantitative differences in the absolute levels and the degrees to which 
different controls had downregulated these genes, the Bcl11b-knockout cells in each 
case express higher levels than the controls.  Although Bcl11a levels in these samples are 
quite low, the Bcl11b-knockout samples derived from protocol I (FLDN) consistently 
delay silencing of Bcl11a relative to controls. 
 
 
Figure S5. Expression patterns of gold standard Bcl11b-regulated genes.  A) Trends in 
expression of gold standard genes: developmental change vs. impacts of loss of Bcl11b. 
Plots show fold change in expression of the 99 gold standard genes when Bcl11b is 
deleted (y axis) plotted against the fold change in the expression of the same genes as 
cells progress from DN1 (ETP) through commitment, to DN2b or DN3 (x axes in left, 
right panels respectively).  Data for fold change in response to Bcl11b deletion are log2 
of the geometric means of effects seen in groups in Table S1B,C. Data for fold changes in 
response to developmental progression are calculated from the difference of the 
geometric means reported in ref. (4)(Table S2 of ref. 4). DN1-to-DN2b values show 
trends in response to in vitro commitment, DN1-to-DN3 values show trends in response 
to in vivo commitment. Note negative correlation between developmental progression 
and Bcl11b knockout effect, suggesting that high upregulation in Bcl11b knockout is 
often linked to DN1-biased (negative x axis value) expression pattern.  B)  Quantitative 
real-time PCR (qPCR) measurements of expression of three Bcl11b-repressed genes, 
Tnni1, Zbtb16, and Kit, in acute response to Bcl11b deletion at the DN3 stage.  Samples of 
sorted DN3 thymocytes from PLBD (Bcl11bfl/fl; ROSA26-Cre-ERT2) and control 
(Bcl11b+/+; ROSA26-Cre-ERT2 = “ERT2Cre”) mice were processed for RNA 
measurement immediately (PLBD DN3, blue) or treated in parallel with 4-OHT and 
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cultured for four more days before re-sorting (ERT2Cre+cult – red bars; PLBD+cult – 
orange bars). In agreement with the surface phenotype shown in Fig. S1B, Bcl11b 
deletion in the Kit-low DN3 starting population led to upregulation of Kit RNA while 
normal developing controls downregulated Kit RNA further under these conditions. 
Tnni1 and Zbtb16 RNAs were low or undetectable (values below baseline) in the 
initially purified DN3 samples but were upregulated dramatically after Bcl11b deletion.   
C) Expression histograms of indicated Bcl11b-dependent gold standard genes, based on 
data from Table S2 of ref. 4. Note rising patterns toward DN3.  D) Expression 
histograms of indicated Bcl11b-repressed gold standard genes, based on data from 
Table S2 of ref. 4.  Note pattern diversity but frequent phase 1 (highest in DN1 and 
DN2a) bias. 
 
 
Figure S6. Properties of the gold standard gene set: KEGG pathway enrichment and 
relation to Bcl11b target genes found at later developmental stages.  A) Top hit 
pathway among genes upregulated in Bcl11b knockout cells is the Natural Killer Cell 
Cytotoxicity pathway. Graphic is from DAVID <https://david.ncifcrf.gov/>, a Kyoto 
Encyclopedia of Genes and Genomes (KEGG) pathway diagram with red stars showing 
the pathway components that are represented among these Bcl11b-repressed gold 
standard genes. Note that sometimes the names under which the genes are listed in the 
KEGG diagram are different from the gene names from GENCODE 1, e.g. TRAIL for 
Tnfsf10.  B) Gold standard genes upregulated in Bcl11b knockout cells were compared 
with genes upregulated in Bcl11b knockout DP cells in the studies of Li et al. (3) and 
Kastner et al. (10), respectively.  We used Table S3 of ref. (3) and Table S2 of ref. (10) as 
sources, clipping off genes that the authors reported to show less than a 2x fold change 
(i.e. for all genes considered, |log2FC| > 1).  Venn diagrams show the overlaps between 
the gene sets, indicating the names of the genes in the shared sets and the names of 
genes included in our gold standard set that were not reported as previous Bcl11b-
affected targets. This could be a slight underestimate, since nomenclature has changed 
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for some genes since publication of refs. (3) and (10).  C) Gold standard genes 
downregulated in Bcl11b knockout cells were compared with genes downregulated in 
Bcl11b knockout DP cells in Li et al., and Kastner et al., selected as in panel (B).  Far 
fewer genes appear to be Bcl11b-dependent in both the early context and the later one, 
as compared to the number of genes that appear to be shared repression targets of 
Bcl11b in both contexts. 
 
 
Figure S7.  Broader patterns of developmental expression of gold standard genes in 
the Immunological Genome microarray data resource.  The figure shows heat maps 
taken from the Immunological Genome (83) web site <www.immgen.org>, using the 
“My Gene Set” interactive heat map tool for seach and display (searched April 27, 2016). 
A) Gold standard genes dependent on Bcl11b were used to interrogate the data 
resource.  Genes are shown in rows. Samples in database define columns.  Orange to 
yellow color means relatively high expression.  Dark blue to blue color means low 
expression.  Columns under the purple bar represent different stages of T-cell 
development, with an orange star at the bottom to indicate DN3a stage. Note that key 
pre-commitment pro-T cell stages here are found in the narrow purple zone to the left 
of the orange star.  Many Bcl11b dependent genes can be seen to peak at DN3a, like 
Bcl11b itself (red arrow on left). B) Bcl11b repressed genes, shown using the same 
convention as in (A).  For internal comparison, the expression pattern of Bcl11b itself 
(red arrow on left) is also loaded with this gene set.  Note that non-T expression of these 
genes (outside the zone marked by purple, top) is not confined to NK cells (light purple 
zone at right), but can also include strikingly high expression in myeloid cells (green, 
pink, red zones) and stem or even B cells (blue zones).  In this panel, the magnification 
does not allow the gene names all to be shown in legible form on the figure itself.  A full 
list of these genes in order from top to bottom is as follows, with the genes marked on 
the figure in bold caps as landmarks: Gimap4, Il2rb, Txk, Fcer1g, Tyrobp, Gstml, Trf, Cd63, 
Cd9, Aoah, Fcgr3, Dok3, Fes, Cd7, Klrd1, Id2, Ccr2, S100a6, Cpa3, KIT, Cd244, Clnk, Gpr97, 
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Iqgap2, Chn2, ZBTB16, Appl2, Klhdc2, Osbpl5, Pear1, Ivns1abp, Sccpdh, 2900026A02Rik, 
Bace1, Ccdc135, ITGA2B, 1700112E06Rik, P2rx1, Kcne3, Col15a1, Arsi, Dlk1, Colq, Cd163l1, 
Chpf, Rgs3, Fdx1, Mcart6, Pgam2, Tnni1, 1700026L01Rik, Fgf3, Tas1r1, Ivns1abp (repeat, 
another probe set), Col9a3, Espn, Fgf15, Pdzk1, Trpm1, Arap3, Lpcat4, Rgs3, Lag3, Mcart6 
(repeat, another probe set), Gramd1a, Polm, Rab19, Ecm1, Timp2, BCL11B, Tnfsf10, Cxcr5, 
Pou2af1, Cd72, Myo1e, Gpr183, Itgb7, Pde2a, Gimap8, Tspan32. 
 
 
Figure S8.  ChIP-sequencing analysis of Bcl11b binding in DN3 cells shows sites of 
engagement at positively and negatively regulated “gold standard” Bcl11b targets 
(A)-(G): Bcl11b occupancy patterns at the indicated genes are shown from two 
independent samples of Bcl11b ChIP-seq and background control samples (1% of ChIP 
input). Thick blue arrows at the top of each panel show the direction of transcription 
and the extent of the transcribed region of the indicated differentially regulated target 
gene.  In (A)-(C), Bcl11b ChIP patterns are compared with patterns of histone H3K4me2 
modification at the DN1 (pre-commitment) and DN2b (immediately post-commitment) 
stages, as measured in ref. (4). A) Bcl11b binding to Tyrobp, a gene that undergoes 
silencing and chromatin closing, as shown by disappearance of a peak in the H3K4me2 
tracks, during commitment. B) Bcl11b binding to the Cd3 gene cluster, three genes that 
undergo upregulation and chromatin opening, as shown by H3K4me2 signals, during 
commitment. C) Bcl11b binding to Tnni1, a gene that is normally silent and closed 
before and after commitment for most αβ-lineage T cells. D) Bcl11b binding to Il2rb. E) 
Bcl11b binding to Zbtb16. F) Bcl11b binding to Cd7.  G) Bcl11b binding to Nfil3. 
Although Nfil3 did not fulfill the criteria to be a “gold standard” gene, it was 
upregulated in many DN2-3 Bcl11b knockout samples as compared to controls, as 
illustrated in Fig. S2. H) Top three motifs enriched in Bcl11b binding peaks in DN3 cells 
are shown. Binding detected by ChIP does not prove function, but these results and 
those in Fig. 3A,B indicate specific candidate sites through which the Bcl11b functions 
demonstrated here may be mediated. 
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Figure S9.  Full representation of the metaclusters in the early T specification SOM.   
A) The positions of all the numbered metaclusters in the total map are shown. Note that 
the map is actually a toroidal surface, which is opened out to a flat presentation simply 
for display. This is the underlying structure of the gene clusters that are differentially 
activated and presented as enriched or depleted signals in Fig. 3C-G.  B) Labeling of 
major SOM regions associated with developmental gene expression change and with 
effects of Bcl11b deletion.  These regions are defined by the differential expression 
patterns shown in Fig. 3C and D.  Region A=genes upregulated during normal pro-T 
cell development.  Region B=genes downregulated during normal pro-T cell 
development, including many phase 1 regulatory genes.  Region C1: genes repressed by 
Bcl11b (upregulated upon Bcl11b deletion) that have expression similarities with phase 
1 genes.  Region C2: genes repressed by Bcl11b (upregulated upon Bcl11b deletion) that 
have no normal expression enrichment in normal pro-T cell development.  In contrast to 
region C1, which overlaps region B, region C2 is apparently disjunct from region A 
despite its proximity. 
 
 
Figure S10. Eigengene expression pattern heatmaps in representative SOM 
metaclusters.  Each metacluster is comprised of multiple SOM unit clusters of genes 
that share related expression patterns across our whole set of RNA-seq samples. These 
collections of gene expression patterns that characterize each metacluster are shown 
here for four metaclusters of interest, in terms of their eigengenes. These are the 
metaclusters in the SOM overall the positions of which are indicated in Fig. 3C. Here, in 
panels (A)-(D), each row of the heatmap depicts the expression levels for the eigengene 
of that SOM unit in each sample.  The number at the left side identifying each row is the 
coordinate of each SOM unit that is included within the indicated metacluster.  The 
developmental stage and treatment used to generate each sample is depicted with 
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different color codes underneath the heatmap, identifying each column.  A) Heatmap of 
metacluster 112.  B) Heatmap of metacluster 212.  C) Heatmap of metacluster 168.  D) 
Heamap of metacluster 26. 
 
 
Figure S11.  Runx3 distal promoter upregulation in Bcl11b knockout cells 
Browser tracks are shown as in Fig. S4, focusing on the distinctive effect of Bcl11b 
deletion on Runx3 expression from the distal promoter. Runx3 transcription units are 
approximately indicated by dark blue arrows, top.  The cyan rectangle over the tracks 
indicates the position of the distal promoter of Runx3.  Although transcripts are 
commonly expressed from the proximal promoter of Runx3 in multiple T-cell subsets, 
expression from the distal promoter is associated with T-cell commitment to a cytolytic 
lineage (84). In the track key on the left, matched pairs of control and Bcl11b-knockout 
samples generated and analyzed within a single experiment are connected by brackets, 
as in Fig. S4. For details of the samples, see Table S5. 
 
 
Figure S12. Trait enrichment for hypothesis testing map of SOM metaclusters, and 
Venn diagrams of Bcl11b regulome overlaps with regulomes of PU.1 and E2A.  A) 
Full comprehensive heatmap of the correlation between SOM metaclusters of the 
indicated numbers and different developmental or treatment traits.  The heatmap is laid 
out with a break at the point shown in order to allow cluster numbers to be legible. 
Metaclusters with significant positive correlation against the traits indicated at the 
bottom are highlighted in red and those with negative correlation are in blue.  To 
retrieve gene lists within each cluster with a desired trait enrichment property, see 
Table S2.   
 For interpretation, note that color scale is relative to averages over the whole 
sample set, but not over all of T-cell biology. Thus, given the preponderance of DN1 
and DN2a/2b samples in this analysis, both phase 1 and phase 1-like, the DN1 stage as 
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such is mainly distinguished here by a relatively small number of more highly 
represented metaclusters, i.e., metaclusters 244, 63, 265, 248, and 264, and 
underrepresentation of only a few later-activated metaclusters, i.e. metaclusters 232, 
193, 64, 200, 184, 26, 25, and 59, despite its large difference from most mature T cells, 
which are not studied here. The nature of the comparison yields more differences 
between Bcl11b KO and control DN2b cells.  
 Also note that “DN2” here primarily refers to experimentally perturbed samples 
which cannot be perfectly equated with either normal DN2a or normal DN2b cells. 
Given the nature of this study, most of them are Bcl11b knockout in this sample set, 
accounting for the large overlap between clusters correlating with “Bcl11b KO” and 
with “DN2”. 
 
B) Venn diagram of effects shared between genes up- and downregulated by Bcl11b 
deletion (this study) and by acute introduction of a PU.1 obligate repressor (PU.1-
ENG)(7). Note lack of bias in directions of shared effects.  
 
C) Venn diagram of effects shared between genes up- and downregulated by Bcl11b 
deletion (this study) and by deletion of the E2A isoform E47 in similar fetal liver-
derived DN2 cells (11). The overlaps are highly biased toward concordance, as shown, 
and a simple χ2 test of dependence between these variables from the 2x2 matrix of 
upregulated and downregulated genes for each perturbation yields a chi-square statistic 
of 18.3, p-value=0.000019. 
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